EMA approved Jascayd: the first drug for the treatment of pulmonary fibrosis
EMA has approved for the first time Jascayd (nerandomilast) for the treatment of idiopathic and progressive pulmonary fibrosis. Advantage of 68.8 mL, mortality reduction of 43%. Learn about the breakthrough in pulmonology.
